Suven Pharmaceuticals share price
You have to be logged in to add this to Watchlist.- ₹1,006.35(-0.03%)June 19, 2025 11:17:50 AM IST
- NSE
- BSE
- Vol : 50.76K (NSE + BSE)Last 20 day avg : 278.43 K
Suven Pharmaceuticals is trading -0.03% lower at Rs 1,006.35 as compared to its last closing price. Suven Pharmaceuticals has been trading in the price range of 1,018.00 & 1,002.45. Suven Pharmaceuticals has given -11.34% in this year & 0.73% in the last 5 days. Suven Pharmaceuticals has TTM P/E ratio 109.31 as compared to the sector P/E of 22.82.There are 6 analysts who have initiated coverage on Suven Pharmaceuticals. There are 3 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 38.73 Crores in its last quarter.Listed peers of Suven Pharmaceuticals include Glenmark Pharmaceuticals (-1.54%), Biocon (2.29%), Suven Pharmaceuticals (-0.03%).The Mutual Fund holding in Suven Pharmaceuticals was at 8.65% in 9 May 2025. The MF holding has increased from the last quarter. The FII holding in Suven Pharmaceuticals was at 7.38% in 9 May 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Jun 19, 2025, 05:54 AM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BHigher than historical values15.15The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values96.89Price-to-earnings ratio based on trailing 12-month earnings
- BetaMedium volatility0.97Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.16The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 58.94% from Rs 402.02 crore to Rs 252.93 crore, year-on-year
The company's profit declined by 27.44% year-on-year during the March quarter, dropping from Rs 53.37 crore to Rs 38.73 crore- The debt to equity of the company is higher than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 1,104.15
- R2
- 1,163.55
- R3
- 1,227.30
- S1
- 981.00
- S2
- 917.25
- S3
- 857.85
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | Bullish | 1,634.55 | -1.54 | 46,127.13 | 35.18 | 5.27 | 0.15 | 7.90 |
| Biocon | Bullish | 350.00 | 2.29 | 42,021.00 | 44.93 | 1.96 | 0.14 | 59.81 |
| Suven Pharmaceuticals | Bearish | 1,006.35 | -0.03 | 38,289.40 | 95.22 | 14.93 | - | 10.36 |
| Laurus Labs | Bullish | 658.80 | -0.69 | 35,720.62 | 112.59 | 7.96 | 0.18 | 15.82 |
| Ipca Laboratories | Bearish | 1,348.15 | -1.05 | 34,198.06 | 39.16 | 4.96 | 0.29 | 8.55 |
- Promoter(s) holds a high stake in the company at 66.41%
- Promoter(s) have increased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 3.67 percentage points from previous quarter
- Mutual Funds holding has decreased by 4.39 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-28 | Audited Results |
| 2025-02-12 | Quarterly Results |
| 2024-11-12 | Quarterly Results |
| 2024-08-09 | Quarterly Results |
| 2024-05-30 | Audited Results |
- IndustryBiotechnology & Drugs
- ISININE03QK01018
- BSE Code543064
- NSE CodeCOHANCE
Suven Pharmaceuticals is trading at 1006.35 as on Thu Jun 19 2025 05:47:50. This is -0.03% lower as compared to its previous closing price of 1006.70.
The market capitalization of Suven Pharmaceuticals is 38289.40 Cr as on Thu Jun 19 2025 05:47:50.
The average broker rating on Suven Pharmaceuticals is Strong Buy. The breakup of analyst rating is given below -
- 3 analysts have given a strong buy rating
- 3 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Suven Pharmaceuticals is 1359.00 whereas the 52 wk low is 696.55
Suven Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 109.31
- Sector P/E: 22.82
- Dividend Yield: 0.00%
- D/E ratio: 0.16
Suven Pharmaceuticals reported a net profit of 264.77 Cr in 2025.
The Mutual Fund Shareholding was 8.65% at the end of 9 May 2025.